Short answer
Teva Pharmaceutical Industries Ltd (TEVA) filed an 8-K current report with the SEC on September 11, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Teva announced pricing of securities on September 10, 2026.
Teva Pharmaceutical Industries Ltd 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Teva announced pricing of securities on September 10, 2026
- Exhibit 99.1 contains the pricing press release and is the key source for deal terms
- Securities pricing may affect Teva’s capital structure and future financing obligations
Item 8.01 · Other Events
- Planned issuance: €1.5B and $3.2B senior notes, totaling five tranches with maturities from 2032 to 2037
- Coupon rates: 4.250% to 4.625% on Euro Notes and 5.250% to 5.750% on USD Notes
- Proceeds increase Teva’s debt burden, while staggered maturities support long-term refinancing and liquidity management
- Notes priced below par at 98.327% to 98.993%, implying issuance proceeds below aggregate principal amounts
- Closing expected September 16, 2026, with Teva providing guarantees for issuer subsidiaries
Item EX-99.1 · Exhibit EX-99.1
- $4.9B senior-notes offering priced across EUR and USD tranches, increasing near-term refinancing capacity
- Coupon rates 4.250% to 5.750%, with maturities spanning 2032 to 2037
- Proceeds target redemption of higher-cost notes, including 6.750%, 7.875%, 7.375% and 8.125% securities
- Planned redemptions include up to $450M due 2027 and up to €1.15B due 2030
- Settlement expected September 16, 2026, subject to customary closing conditions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Teva Pharmaceutical Industries Ltd 8-K filings
Get the next TEVA 8-K as it lands
Follow TEVA for push alerts, or ask the research agent what this filing means.